CCL11 is a ligand for the chemokine receptor type 3 (CCR3) receptor and, thus, CCR3 has been identified as a potential therapeutic target for Alzheimer’s disease that reduces amyloid beta deposition and tau phosphorylation [35]. Here, MAPT is linked to Alzheimer disease.